Department of Gynecology and Obstetrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ageing Clinical & Experimental Research Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
Eur J Med Res. 2023 Jan 27;28(1):51. doi: 10.1186/s40001-023-01007-8.
This study is aimed to compare the effect of oral misoprostol with vaginal misoprostol to induce labor as a systematic review and meta-analysis.
Electronic databases including PubMed [Medline], Scopus, Web of science, Embase, Ovid, Cochrane library, and ClinicalTrials.gov were searched using the relevant keywords. All RCTs comparing the effect of oral vs vaginal misoprostol on labor induction were considered. The Cochrane Risk of Bias checklist was used for assessing quality of included RCTs. All statistical analyses were completed using STATA (Version 16) and Revman (Version 5).
Thirty-three RCTs with 5162 patients (1560 in oral and 2602 in vaginal groups) were included in this meta-analysis. Labor induction length did differ significantly between the two routes of misoprostol administration [Standardized Mean Difference: 0.40 h, 95% confidence interval (CI) 0.34, 0.46; I: 66.35%; P = 0.04]. In addition, the risk of neonatal death, tachysystole, uterine hyperstimulation, preeclampsia, non-FHR and abortion was lower in the oral misoprostol group and the risk of hypertonus, PROM, oxytocin need and cesarean fever was higher in this group than the vaginal misoprostol group.
Based on results of this meta-analysis, it can be inferred that currently, clinical specialists can decide to use this drug orally or vaginally on a case-by-case basis, depending on the condition of the pregnant mother and the baby.
本研究旨在通过系统评价和荟萃分析比较口服米索前列醇与阴道米索前列醇引产的效果。
使用相关关键词检索电子数据库,包括 PubMed[Medline]、Scopus、Web of science、Embase、Ovid、Cochrane 图书馆和 ClinicalTrials.gov。所有比较口服与阴道米索前列醇引产效果的 RCT 均被认为是相关的。使用 Cochrane 偏倚风险检查表评估纳入 RCT 的质量。所有统计分析均使用 STATA(版本 16)和 Revman(版本 5)完成。
这项荟萃分析纳入了 33 项 RCT 共 5162 名患者(口服组 1560 例,阴道组 2602 例)。两种途径使用米索前列醇引产的时间长短存在显著差异[标准化均数差:0.40 小时,95%置信区间(CI)0.34,0.46;I:66.35%;P=0.04]。此外,口服米索前列醇组新生儿死亡、心动过速、子宫过度刺激、子痫前期、非胎儿心率和流产的风险较低,而该组的子宫张力过高、胎膜早破、催产素需要和剖宫产发热的风险较高。
根据这项荟萃分析的结果,可以推断目前,临床专家可以根据孕妇和婴儿的情况,个案决定使用这种药物口服或阴道使用。